Endocannabinoid system and cardiometabolic risk

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 5, 2007, Pages 591-594

  Saavedra, L E ^a  

^a Asociacion Cardiovascular Centroccidental Venezuela   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ADIPONECTIN; ANANDAMIDE; ANGIOTENSINOGEN; C REACTIVE PROTEIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; DRONABINOL; ENDOCANNABINOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; RIMONABANT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ADIPOSE TISSUE; AGGRESSIVENESS; ANXIETY; APPETITE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENERGY METABOLISM; FOOD INTAKE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTHALAMUS; INSOMNIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; MOOD DISORDER; NEUROLOGIC DISEASE; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SMOKING CESSATION; SUICIDAL BEHAVIOR; WAIST CIRCUMFERENCE;

ABDOMINAL FAT; ADIPOKINES; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDOCANNABINOIDS; HUMANS; INSULIN RESISTANCE; LIPIDS; OBESITY; OVERWEIGHT; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; WEIGHT LOSS;

EID: 35448937290     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100373     Document Type: Review

References (31)

1. Lopez, A.D., Mathers, C.D., Ezzati, M., Jamison, D.T. & Murray, C.J.L. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367, 1747-1757 (2006).
2. Unal, B., Critchley, J.A. & Capewell, S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 109, 1101-1107 (2004).
3. Ford, E.S. et al. Explaining the decrease in US deaths from coronary disease, 1980-2000. N. Engl. J. Med. 356, 2388-2398 (2007).
4. Romero-Corral, A. et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 368, 666-678 (2006).
5. Yusuf, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937-952 (2004).
6. Yusuf, S. et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366, 1640-1649 (2005).
7. Lanas, F. et al. Risk factors for acute myocardial infarction in Latin America. The INTERHEART Latin American Study. Circulation 115, 1067-1074 (2007).
8. Guerre-Millo, M. Adipose tissue and adipokines: for better or worse. Diabetes Metab. 30, 13-19 (2004).
9. Yu, Y.H. & Ginsberg, H.N. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ. Res. 96, 1042-1052 (2005).
10. Despres, J.P. Abdominal obesity: the most prevalent cause of metabolic syndrome and related cardiometabolic risk. Eur. Heart J. Suppl. 8, B4-B12 (2006).
11. de Koning, L., Merchant, A.T., Pogue, J. & Anand, S.S. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur. Heart J. 28, 850-856 (2007).
12. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002).
13. Alberti, K.G.M., Zimmet, P., Shaw, J. & for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 366, 1059-1062 (2005).
14. Grundy, S.M. et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation 112, 2735-2752 (2005).
15. Deedwania, P.D. et al. Reduction of low density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368, 919-928 (2006).
16. Lakka, H.M. et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288, 2709-2716 (2002).
17. Isomaa, B. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683-689 (2001).
18. Daly, C.A. et al. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease. Data from the EUROPA trial. Heart (2007); e-pub ahead of print (doi:10.1136/hrt.2006.113084).
19. Kahn, R., Buse, J., Ferrannini, E. & Stern, M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28, 2289-2304 (2005).
20. De Petrocellis, L., Cascio, M.G. & Di Marzo, V. The endocannabinoid system: a general view and latest additions. Br. J. Pharmacol. 141, 765-774 (2004).
21. Pagotto, U. & Pasquali, R. Endocannabinoids and energy metabolism. J. Endocrinol. Invest. 29 (suppl. 3), 66-73 (2006).
22. Gelfand, E.V. & Cannon, C.P. Rimonabant: a cannabinoid receptor type 1 blocker for the management of multiple cardiometabolic risk factors. J. Am. Coll. Cardiol. 47, 1919-1926 (2006).
23. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C. & Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564 (1990).
24. Di Marzo, V., Bifulco, M. & De Petrocellis, L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3, 771-784 (2004).
25. Woods, S.E. The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance. Am. J. Med. 120, S9-S17 (2007).
26. Osei-Hyiaman, D. et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115, 1298-1305 (2005).
27. Van Gaal, L.F., Rissanen, A.M., Scheen, A.J., Ziegler, O. & Rossner, S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389-1397 (2005).
28. Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J., Rosenstock, J. & for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295, 761-775 (2006).
29. Despres, J.P., Golay, A. & Sjostrom, L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121-2134 (2005).
30. Scheen, A.J., Finer, N., Hollander, P., Jensen, M.D., Van Gaal, L.F. & for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368, 1660-1672 (2006).
31. Reid, R.D., Quinlan, B., Riley, D.L. & Pipe, A.L. Smoking cessation: lessons learned from clinical trial evidence. Curr. Opin. Cardiol. 4, 280-285 (2007).